Literature DB >> 16782958

Does intravitreal injection of bevacizumab have an effect on the blood-aqueus barrier function?

F Ziemssen, M Warga, I M Neuhann, M Leitritz, S Biester, S Grisanti, K U Bartz-Schmidt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16782958      PMCID： PMC1857155          DOI： 10.1136/bjo.2006.092262

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  5 in total

1.  Anterior chamber flare after trabeculectomy and after phacoemulsification.

Authors:  D Siriwardena; A Kotecha; D Minassian; J K Dart; P T Khaw
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

Review 2.  Laser tyndallometry in anterior segment diseases.

Authors:  M Küchle
Journal:  Curr Opin Ophthalmol       Date:  1994-08       Impact factor: 3.761

3.  Measurement of aqueous cells and flare in normal eyes.

Authors:  S M Shah; D J Spalton; S E Smith
Journal:  Br J Ophthalmol       Date:  1991-06       Impact factor: 4.638

4.  Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; Andrew A Moshfeghi; Carmen A Puliafito
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2005 Jul-Aug

Review 5.  Regulation of vascular permeability by vascular endothelial growth factors.

Authors:  D O Bates; S J Harper
Journal:  Vascul Pharmacol       Date:  2002-11       Impact factor: 5.773
  5 in total
  6 in total

1.  Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).

Authors:  Lihteh Wu; María A Martínez-Castellanos; Hugo Quiroz-Mercado; J Fernando Arevalo; María H Berrocal; Michel E Farah; Mauricio Maia; José A Roca; Francisco J Rodriguez
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-03       Impact factor: 3.117

Review 2.  [(Side) effects of VEGF inhibition].

Authors:  F Ziemssen; K U Bartz-Schmidt; S Grisanti
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

Review 3.  Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.

Authors:  Michael Waisbourd; Anat Loewenstein; Michaella Goldstein; Igal Leibovitch
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 4.  Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Authors:  Focke Ziemssen; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt; Martin S Spitzer
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 5.  Bevacizumab: off-label use in ophthalmology.

Authors:  Salvatore Grisanti; Focke Ziemssen
Journal:  Indian J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.848

6.  Bevacizumab in Wet AMD treatment: A tribute to the thirteen years of experience from the beginning of the anti-VEGF era in Romania.

Authors:  Horia T Stanca; Simona Stanca; Bogdana Tabacaru; Madalina Boruga; Florian Balta
Journal:  Exp Ther Med       Date:  2019-08-06       Impact factor: 2.447
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.